



```

QY 256 TGCTGAGCGCGGATGTTCTCTCAACCCCTCCCGCCCGCGCTGTAGAGAAAGCT 315
Db 241 TGCTGAGCGCGGATGTTCTCTCAACCCCTCCCGCCCGCGCTGTAGAGAAAGCT 300
QY 316 TCCAGTACATTGACCTCCATAGAGATGATTTGTGACAGCGCTGAAGAGTGGTGCCA 375
Db 301 TCCAGTACATTGACCTCCATAGAGATGATTTGTGACAGCGCTGAAGAGTGGTGCCA 360
QY 376 TCGAGAGGAGCTCTGTCCAGCTGTGCTCGCTTCAAGCAAGACTCTTCAGAAATGATG 435
Db 361 TCGAGAGGAGCTCTGTCCAGCTGTGCTCGCTTCAAGCAAGACTCTTCAGAAATGATG 420
QY 436 CCGTGGCTGGGAGACCGCTGACGCGCTGGGGCCCGGTGTGGCTCGAGTGAACATGGGTC 495
Db 421 CCGTGGCTGGGAGACCGCTGACGCGCTGGGGCCCGGTGTGGCTCGAGTGAACATGGGTC 480
QY 496 CTCAGCAGCTGCCCGATGTGTCAGAGTCTTCCAAATACCTCCCGTATCTGTGGCCGAATG 555
Db 481 CTCAGCAGCTGCCCGATGTGTCAGAGTCTTCCAAATACCTCCCGTATCTGTGGCCGAATG 540
QY 556 GGAGCGATCCCAAGCAAGGACCGGTGTCTTACGCGCACTTGGAGCTGAGCTGCTG 615
Db 541 GGAGCGATCCCAAGCAAGGACCGGTGTCTTACGCGCACTTGGAGCTGAGCTGCTG 600
QY 616 ACCGGGCGATGGGTGGCTCACGAGCCCTATGTGTGACGAGAGTGAACGGAACTTT 675
Db 601 ACCGGGCGATGGGTGGCTCACGAGCCCTATGTGTGACGAGAGTGAACGGAACTTT 660
QY 676 ATGACGACAGAGCGACCGACAAAGAGCCCTGTCTTGGTGGATCAATGCTGTGACG 735
Db 661 ATGACGACAGAGCGACCGACAAAGAGCCCTGTCTTGGTGGATCAATGCTGTGACG 720
QY 736 CCTTCAGAGCCCTGAGCAAGATCTTCTGTGAATCAATGATCATTTAGAGGGAGTGG 795
Db 721 CCTTCAGAGCCCTGAGCAAGATCTTCTGTGAATCAATGATCATTTAGAGGGAGTGG 780
QY 796 AAGAGGCTGGCTGTGTCCTGTGAGGAACTTGTGAAAAAGAAAGAACCGATCTTCT 855
Db 781 AAGAGGCTGGCTGTGTCCTGTGAGGAACTTGTGAAAAAGAAAGAACCGATCTTCT 840
QY 856 CTGGTGTGACACTATGTTGTAATTTCAATATCCTGTGTGATGACCAAGAGCCAGCA 915
Db 841 CTGGTGTGACACTATGTTGTAATTTCAATATCCTGTGTGATGACCAAGAGCCAGCA 900
QY 916 TCACCTATGGAACCCGGGGGAGACGTAATTCATGAGTGAAGTGAATGACAGACAG 975
Db 901 TCACCTATGGAACCCGGGGGAGACGTAATTCATGAGTGAAGTGAATGACAGACAG 960
QY 976 ATTTTCACTAGGAACTTTGTGTGACATCTTCAATGAACCAATGGCTGATCTGGTTCTC 1035
Db 961 ATTTTCACTAGGAACTTTGTGTGACATCTTCAATGAACCAATGGCTGATCTGGTTCTC 1020
QY 1036 TTCTCGGTACCTGTGTGATCTCGTGTGTATATCTGTGTCTGTGAATCTATGATGAG 1095
Db 1021 TTCTCGGTACCTGTGTGATCTCGTGTGTATATCTGTGTCTGTGAATCTATGATGAG 1080
QY 1096 TGGTCTCTCTTACAGAAAGAGAAATAATATACATAAGCAAGCCATCCATCTAGACTAGA 1155
Db 1081 TGGTCTCTCTTACAGAAAGAGAAATAATATACATAAGCAAGCCATCCATCTAGACTAGA 1140
QY 1156 AATACCGGAATAGACAGCGGGTTGAGAAATTTGTGTGATCTGATCTAAGAGAGATTCTAA 1215
Db 1141 AATACCGGAATAGACAGCGGGTTGAGAAATTTGTGTGATCTGATCTAAGAGAGATTCTAA 1200
QY 1216 TGAACCTCTGAGAGTACCCATCTCTTTCTATTCATGAGAGTGAAGGCGCTTTGATGAGC 1275
Db 1201 TGAACCTCTGAGAGTACCCATCTCTTTCTATTCATGAGAGTGAAGGCGCTTTGATGAGC 1260
QY 1276 CTGGAACATAAAGATCATATCTGCGCGAGGATTAAGAAAAATTTCAATCGGTCTAGTCC 1335
Db 1261 CTGGAACATAAAGATCATATCTGCGCGAGGATTAAGAAAAATTTCAATCGGTCTAGTCC 1320

```

```

QY 1336 CTCACATGATGTGTCTGGGGTGGAAAAAAGGTGACACGATCTTGAAGATGTGCT 1395
Db 1321 CTCACATGATGTGTCTGGGGTGGAAAAAAGGTGACACGATCTTGAAGATGTGCT 1380
QY 1396 CCAAAAGAAATAGTTCACAAAGATGTGTGTTCCATGACTAGACTACACCCGTGA 1455
Db 1381 CCAAAAGAAATAGTTCACAAAGATGTGTGTTCCATGACTAGACTACACCCGTGA 1440
QY 1456 TTGCAATATTTGACACCCAGTATCTGACGCAAAAAAGAGGATCAAGACGTGTTG 1515
Db 1441 TTGCAATATTTGACACCCAGTATCTGACGCAAAAAAGAGGATCAAGACGTGTTG 1500
QY 1516 GAACAGAACAGATATGATCCGGATGATTCACCATTCCTCAATGGCAAAATGTTCCAG 1575
Db 1501 GAACAGAACAGATATGATCCGGATGATTCACCATTCCTCAATGGCAAAATGTTCCAG 1560
QY 1576 AGATCGTCCACAAAGACGTGTGTCTAATTCGCTGGAGACTGTGATGATGAGAACTT 1635
Db 1561 AGATCGTCCACAAAGACGTGTGTCTAATTCGCTGGAGACTGTGATGATGAGAACTT 1620
QY 1636 CGCAGAAATGAAATCAACAGTGGAACTACATGAGGGAACCAATATTTGCTGCT 1695
Db 1621 CGCAGAAATGAAATCAACAGTGGAACTACATGAGGGAACCAATATTTGCTGCT 1680
QY 1696 TTTTCTTAGAGATGGCCAGCTCCATTAATCAAGAACTTCTAGTCTGATCTGATCA 1755
Db 1681 TTTTCTTAGAGATGGCCAGCTCCATTAATCAAGAACTTCTAGTCTGATCTGATCA 1740
QY 1756 CTGACAGATTCACTTCCCAACATCCCTAGACAGGATGGAATGTAATATCCAGAGAT 1815
Db 1741 CTGACAGATTCACTTCCCAACATCCCTAGACAGGATGGAATGTAATATCCAGAGAT 1800
QY 1816 TTGGGTCTAGTATGATGACATTTTCCCTGCAATTTAAATGTTGGAGATCTGATGAC 1875
Db 1801 TTGGGTCTAGTATGATGACATTTTCCCTGCAATTTAAATGTTGGAGATCTGATGAC 1860
QY 1876 TAATAAAATATTTCAAGGACAGATGTTGAAATGTTAAGTCCCACTGACACACC 1935
Db 1861 TAATAAAATATTTCAAGGACAGATGTTGAAATGTTAAGTCCCACTGACACACC 1920
QY 1936 TTCTCAAGTCAATAGCTGTGTCAGCAACCTTATGCAATCTGCAATGAGCC 1995
Db 1921 TTCTCAAGTCAATAGCTGTGTCAGCAACCTTATGCAATCTGCAATGAGCC 1980
QY 1996 AGATTTGATTTCTTCCCACTTTTATGCAATCTGCAACCTTGAATTTGATGACATTA 2055
Db 1981 AGATTTGATTTCTTCCCACTTTTATGCAATCTGCAACCTTGAATTTGATGACATTA 2040
QY 2056 TCACTCCGTTGCTTTTCTAGGCTCTCAAGTCTGTGACACATATCATTCATCAAT 2115
Db 2041 TCACTCCGTTGCTTTTCTAGGCTCTCAAGTCTGTGACACATATCATTCATCAAT 2100
QY 2116 GATGCTCTTGTCTTACCACTCTTCTTATCTTATTAATTAATGTTG 2167
Db 2101 GATGCTCTTGTCTTACCACTCTTCTTATCTTATTAATTAATGTTG 2152

```

```

RESULT 2
AA10638/c
ID AA10638 standard; DNA; 127 BP.
XX
XX AA10638;
XX
XX 30-MAR-1999 (first entry)
XX
XX Human biallelic polymorphic DNA fragment WI-15225.
XX
XX Polymorphism; biallelic; human; forensic; paternity testing; disease;
XX detection; phenotypic typing; characteristic; infection; hereditary;
XX autoimmune disease; cancer; inflammation; drug; therapy; medication;
XX treatment; marker; ss.
XX
XX Homo sapiens.
OS

```

PN	XX	MO9820165-A2.
PD	XX	14-MAY-1998.
PE	XX	05-NOV-1997;
PF	XX	97WO-USO20313.
PG	XX	06-NOV-1996;
PH	XX	96US-0030455P.
PI	XX	(WHEED ) WHITEHEAD INST BIOMEDICAL RES.
PJ	XX	Lander ES, Wang D, Hudson T;
PK	XX	WPI; 1998-286974/25.
PL	XX	New isolated nucleic acid segments from the human genome - used for
PM	XX	determining polymorphic forms for use in e.g. forensics, paternity
PN	XX	testing or phenotypic typing for disease.
PO	XX	Claim 1; Page 67; 310pp; English.
PP	XX	AA10269-X12937 are human DNA fragments which contain biallelic
PQ	XX	polymorphic markers which have been isolated using the primers
PR	XX	represented in AA09121-X10268. The base occupying the polymorphic site
PS	XX	is indicated by the appropriate IUPAC-IUB ambiguity code. These fragments
PT	XX	can be used in methods for determining polymorphic forms in an individual
PV	XX	for use in e.g. forensics, paternity testing or for phenotypic typing for
PW	XX	diseases such as agammaglobulinemia, diabetes insipidus, Leech-Nyhan
PX	XX	syndrome, muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease,
PY	XX	familial hypercholesterolemia, polycystic kidney disease, hereditary
PZ	XX	spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary
QA	XX	haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
QB	XX	syndrome, osteogenesis imperfecta, acute intermittent porphyria,
QC	XX	autoimmune diseases, inflammation, cancer, diseases of the nervous
QD	XX	system, infection by pathogenic microorganisms, and characteristics such
QE	XX	as longevity, appearance (e.g. baldness, obesity), strength, speed,
QF	XX	endurance, fertility, and susceptibility or receptivity to particular
QG	XX	drugs or therapeutic treatments. The isolated polymorphic nucleic acid
QH	XX	segments can also be used to produce medicaments for the treatment or
QI	XX	prophylaxis of such diseases
QJ	XX	Sequence 127 BP; 47 A; 16 C; 36 G; 27 T; 0 U; 1 Other;
QK	XX	Query Match 5.6%; Score 126.6; DB 1; Length 127;
QL	XX	Best Local Similarity 99.2%; Pred. No. 9.2;
QM	XX	Matches 126; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QN	XX	2017 TTTTAGCATTACTCCAACTTCGATTTGATGGCATATACACTCGGTTTGCTTTAG 2076
QO	XX	127 TTTTAGCATTACTCCAACTTCGATTTGATGGCATATACACTCGGTTTGCTTTAG 68
QP	XX	2077 GTCTCAAGTGTCTGACACATTAATTCATTCATCAATGATGCGCTTTGCTTACACT 2138
QQ	XX	67 GTCTCAAGTGTCTGACACATTAATTCATTCATCAATGATGCGCTTTGCTTACACT 8
QR	XX	2137 CTTTCT 2143
QS	XX	7 CTTTCT 1
QT	XX	RESULT 3
QU	XX	AAV81394
QV	XX	AAV81394 standard; DNA; 1733 BP.
QW	XX	AAV81394;
QX	XX	16-MAR-1999 (first entry)
QY	XX	Human tumour antigen zsg15 coding sequence.
QZ	XX	Secretion; differentiation marker; tumour; epithelial cell; colon; blood;
RA	XX	breast; prostate; growth; development; antagonist; receptor; bone marrow;
RB	XX	cancer; metastasis; ss.

XX	Homo sapiens.
OS	
XX	
FH	Key
FT	CDS
FT	Location/Qualifiers 34..1347 /*tag= a /product= "zsig15"
FT	
XX	
PN	MO9850552-A1.
XX	
PD	12-NOV-1998.
XX	
PF	06-MAY-1998; 98WO-US009584.
PR	06-MAY-1997; 97US-0045703P.
XX	
PA	(Zymo.) ZYMOGENETICS INC. Sheppard PO, Grossmann A; WPI; 1999-034723/03. P-PSDB; AAM67722.
DR	
XX	
PT	New nucleic acid encoding secreted polypeptide zsig15 - used as a marker for tumour cells, useful for diagnosis and treatment of cancers, inflammation and hyperplasia.
PT	
PS	Claim 4; Page 81-84; 100pp; English.
XX	
CC	This sequence encodes a secreted polypeptide, designated zsig15, which is a marker for differentiation in normal and tumour cells (particularly epithelial cells and derived tumours of colon, breast and prostate). The zsig15 protein is useful for the promotion of growth and development of epithelial cells, to identify specific (ant)agonists, also where conjugated to a toxin, to deliver these to cells expressing the cognate receptor (e.g. to kill cells of blood, colon, breast and bone marrow cancer), and to identify/isolate receptors involved in cancer metastases. The sequence was isolated from a colon cancer library after screening an EST (expressed sequence tag) database for sequences containing putative secretion signal sequences
CC	
XX	
SQ	Sequence 1733 BP; 448 A; 504 C; 442 G; 339 T; 0 U; 0 Other;
	Query Match 2.8%; Score 62.4; DB 1; Length 1733;
	Best Local Similarity 96.9%; Pred.No.1.3;
	Matches 63; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy	2178 CTGCNCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2233
Dd	1559 CTTTCTCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1655
Oy	2238 AAAAA 2242
Dd	1659 AAAAA 1663
	RESULT 4
ID	AA265270/c
XX	AA265270 standard; DNA; 2152 BP.
AC	AA265270;
DT	23-MAR-2000 (first entry)
DE	Human secreted protein gene 21.
XX	
KM	Human; secreted protein; cancer; tumour; developmental abnormality;
KM	foetal deficiency; blood disorder; immune system disorder; inflammation;
KM	autoimmune disease; allergy; Alzheimer's disease; cognitive disorder;
KM	scleroderma; arthritis; asthma; psoriasis; sepsis; skin disorder;
KM	atherosclerosis; diabetes; cardiovascular disorder; kidney disorder;
KM	digestive disorder; endocrine disorder; infection; AIDS; leukaemia;
KM	therapy; chromosome 18q22-23; ds.